ropinirole has been researched along with Disease Models, Animal in 26 studies
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This was combined with two different doses of fluoxetine (10 and 20 mg/kg)." | 5.37 | Evaluation of antidepressant activity of ropinirole coadministered with fluoxetine in acute and chronic behavioral models of depression in rats. ( Ghorpade, S; Manjrekar, N; Sonawane, D; Tripathi, R, 2011) |
| "A rat model of Parkinson's disease was created by unilaterally infusing 6-hydroxydopamine, a dopamine neurotoxin, into the medial forebrain bundle." | 1.46 | D-512, a novel dopamine D ( Bishop, C; Conti, MM; Das, B; Dutta, AK; Lindenbach, D; Meadows, SM, 2017) |
| " Pharmacokinetic results of CSNE(ROP) in Wistar rat brain and plasma showed a significantly high (p** < 0." | 1.42 | Nano-ropinirole for the management of Parkinsonism: blood-brain pharmacokinetics and carrier localization. ( Ahuja, A; Al Rohaimi, AH; Ali, J; Baboota, S; Hassan, AA; Muslim, S; Mustafa, G, 2015) |
| " Intranasal drug administration may be useful for Parkinson's treatment because this route avoids first-pass metabolism and increases bioavailability in the brain." | 1.39 | Intranasal and subcutaneous administration of dopamine D3 receptor agonists functionally restores nigrostriatal dopamine in MPTP-treated mice. ( Chen, JC; Hsieh, YT; Kuo, YH; Lao, CL, 2013) |
| " Study of pharmacokinetic parameters (AUC, C(max), and T(max)) revealed a greater and more extended release of ropinirole from nanoemulsion gel compared to that from a conventional gel (RPG) and oral marketed tablet (Ropitor)." | 1.38 | Oil based nanocarrier system for transdermal delivery of ropinirole: a mechanistic, pharmacokinetic and biochemical investigation. ( Ahmad, FJ; Azeem, A; Iqbal, Z; Khar, RK; Negi, LM; Talegaonkar, S, 2012) |
| " This was combined with two different doses of fluoxetine (10 and 20 mg/kg)." | 1.37 | Evaluation of antidepressant activity of ropinirole coadministered with fluoxetine in acute and chronic behavioral models of depression in rats. ( Ghorpade, S; Manjrekar, N; Sonawane, D; Tripathi, R, 2011) |
| "The role of iron in the pathogenesis of Parkinson's disease (PD) has been implicated strongly because of generation of oxidative stress leading to dopamine cell death." | 1.36 | Discovery of 4-(4-(2-((5-Hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)(propyl)amino)ethyl)piperazin-1-yl)quinolin-8-ol and its analogues as highly potent dopamine D2/D3 agonists and as iron chelator: in vivo activity indicates potential application in sympto ( Antonio, T; Dutta, AK; Ghosh, B; Reith, ME, 2010) |
| "Ropinirole, which is a non-ergot dopamine agonist derivative, exerts therapeutic benefits in Parkinson's disease (PD)." | 1.34 | Overexpression of D2/D3 receptors increases efficacy of ropinirole in chronically 6-OHDA-lesioned Parkinsonian rats. ( Borlongan, CV; Hara, K; Kim, KM; Maki, M; Matsukawa, N; Morgan, JC; Sethi, KD; Xu, L; Yasuhara, T; Yu, G, 2007) |
| "Ropinirole was weakly neuroprotective in this model." | 1.32 | S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity in comparison to ropinirole. ( Brocco, M; Brotchie, J; Crossman, A; Di Cara, B; Gobert, A; Hill, M; Jackson, M; Jenner, P; Joyce, JN; McGuire, S; Millan, MJ; Peglion, JL; Smith, L, 2004) |
| "Ropinirole was less potent than S32504 in this procedure, and it was likewise less potent than S32504 (0." | 1.32 | S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: III. Actions in models of potential antidepressive and anxiolytic activity in comparison with ropinirole. ( Brocco, M; Dekeyne, A; La Rochelle, CD; Millan, MJ; Papp, M; Peglion, JL; Serres, F; Sharp, T, 2004) |
| "They display some memory deficits as in human Parkinson's desease." | 1.31 | The frissonnant mutant mouse, a model of dopamino-sensitive, inherited motor syndrome. ( Baillet, C; Callizot, N; Guénet, JL; Poindron, P; Warter, JM, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (38.46) | 29.6817 |
| 2010's | 13 (50.00) | 24.3611 |
| 2020's | 3 (11.54) | 2.80 |
| Authors | Studies |
|---|---|
| Ghosh, B | 2 |
| Antonio, T | 3 |
| Zhen, J | 1 |
| Kharkar, P | 1 |
| Reith, ME | 2 |
| Dutta, AK | 3 |
| Modi, G | 1 |
| Reith, M | 1 |
| Dutta, A | 1 |
| Solinski, HJ | 1 |
| Dranchak, P | 1 |
| Oliphant, E | 1 |
| Gu, X | 1 |
| Earnest, TW | 1 |
| Braisted, J | 1 |
| Inglese, J | 1 |
| Hoon, MA | 1 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Naz, F | 1 |
| Fatima, M | 1 |
| Naseem, S | 1 |
| Khan, W | 1 |
| Mondal, AC | 1 |
| Siddique, YH | 1 |
| Nehal, N | 1 |
| Nabi, B | 1 |
| Rehman, S | 1 |
| Pathak, A | 1 |
| Iqubal, A | 1 |
| Khan, SA | 1 |
| Yar, MS | 1 |
| Parvez, S | 1 |
| Baboota, S | 2 |
| Ali, J | 2 |
| Lindenbach, D | 1 |
| Das, B | 1 |
| Conti, MM | 1 |
| Meadows, SM | 1 |
| Bishop, C | 1 |
| Lao, CL | 1 |
| Kuo, YH | 1 |
| Hsieh, YT | 1 |
| Chen, JC | 1 |
| Shin, E | 2 |
| Lisci, C | 1 |
| Tronci, E | 1 |
| Fidalgo, C | 1 |
| Stancampiano, R | 1 |
| Björklund, A | 2 |
| Carta, M | 3 |
| Mustafa, G | 1 |
| Ahuja, A | 1 |
| Al Rohaimi, AH | 1 |
| Muslim, S | 1 |
| Hassan, AA | 1 |
| Yang, C | 1 |
| Zhang, JR | 1 |
| Chen, L | 1 |
| Ge, SN | 1 |
| Wang, JL | 1 |
| Yan, ZQ | 1 |
| Jia, D | 1 |
| Zhu, JL | 1 |
| Gao, GD | 1 |
| Tsuchioka, A | 1 |
| Oana, F | 1 |
| Suzuki, T | 1 |
| Yamauchi, Y | 1 |
| Ijiro, T | 1 |
| Kaidoh, K | 1 |
| Hiratochi, M | 1 |
| Azeem, A | 1 |
| Talegaonkar, S | 1 |
| Negi, LM | 1 |
| Ahmad, FJ | 1 |
| Khar, RK | 1 |
| Iqbal, Z | 1 |
| Garcia, J | 1 |
| Winkler, C | 1 |
| Ghorpade, S | 1 |
| Tripathi, R | 1 |
| Sonawane, D | 1 |
| Manjrekar, N | 1 |
| Ravenscroft, P | 2 |
| Chalon, S | 1 |
| Brotchie, JM | 2 |
| Crossman, AR | 2 |
| Millan, MJ | 3 |
| Di Cara, B | 1 |
| Hill, M | 1 |
| Jackson, M | 1 |
| Joyce, JN | 1 |
| Brotchie, J | 1 |
| McGuire, S | 1 |
| Crossman, A | 1 |
| Smith, L | 1 |
| Jenner, P | 1 |
| Gobert, A | 1 |
| Peglion, JL | 2 |
| Brocco, M | 2 |
| Papp, M | 1 |
| Serres, F | 1 |
| La Rochelle, CD | 1 |
| Sharp, T | 1 |
| Dekeyne, A | 1 |
| Silverdale, MA | 1 |
| Nicholson, SL | 1 |
| Salamone, JD | 1 |
| Carlson, BB | 1 |
| Rios, C | 1 |
| Lentini, E | 1 |
| Correa, M | 1 |
| Wisniecki, A | 1 |
| Betz, A | 1 |
| Lundblad, M | 1 |
| Usiello, A | 1 |
| Håkansson, K | 1 |
| Fisone, G | 1 |
| Cenci, MA | 1 |
| Qu, S | 1 |
| Le, W | 1 |
| Zhang, X | 1 |
| Xie, W | 1 |
| Zhang, A | 1 |
| Ondo, WG | 1 |
| Matsukawa, N | 1 |
| Maki, M | 1 |
| Yasuhara, T | 1 |
| Hara, K | 1 |
| Yu, G | 1 |
| Xu, L | 1 |
| Kim, KM | 1 |
| Morgan, JC | 1 |
| Sethi, KD | 1 |
| Borlongan, CV | 1 |
| Callizot, N | 1 |
| Guénet, JL | 1 |
| Baillet, C | 1 |
| Warter, JM | 1 |
| Poindron, P | 1 |
| Medico, M | 1 |
| De Vivo, S | 1 |
| Tomasello, C | 1 |
| Grech, M | 1 |
| Nicosia, A | 1 |
| Castorina, M | 1 |
| D'Agata, MA | 1 |
| Rampello, L | 1 |
| Lempereur, L | 1 |
| Drago, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized, Placebo-controlled, Double-blind Pilot Trial to Evaluate the Safety and Efficacy of Ropinirole in Motor Recovery After Stroke[NCT00221390] | Phase 2 | 52 participants (Anticipated) | Interventional | 2003-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for ropinirole and Disease Models, Animal
| Article | Year |
|---|---|
Ropinirole silver nanocomposite attenuates neurodegeneration in the transgenic Drosophila melanogaster model of Parkinson's disease.
Topics: alpha-Synuclein; Animals; Animals, Genetically Modified; Antiparkinson Agents; Disease Models, Anima | 2020 |
25 other studies available for ropinirole and Disease Models, Animal
| Article | Year |
|---|---|
Development of (S)-N6-(2-(4-(isoquinolin-1-yl)piperazin-1-yl)ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]-thiazole-2,6-diamine and its analogue as a D3 receptor preferring agonist: potent in vivo activity in Parkinson's disease animal models.
Topics: Animals; Antiparkinson Agents; Benzothiazoles; CHO Cells; Cricetinae; Cricetulus; Disease Models, An | 2010 |
Discovery of 4-(4-(2-((5-Hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)(propyl)amino)ethyl)piperazin-1-yl)quinolin-8-ol and its analogues as highly potent dopamine D2/D3 agonists and as iron chelator: in vivo activity indicates potential application in sympto
Topics: Animals; Disease Models, Animal; Guanosine 5'-O-(3-Thiotriphosphate); Humans; Iron Chelating Agents; | 2010 |
Structural modifications of neuroprotective anti-Parkinsonian (-)-N6-(2-(4-(biphenyl-4-yl)piperazin-1-yl)-ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine (D-264): an effort toward the improvement of in vivo efficacy of the parent molecule.
Topics: Animals; Benzothiazoles; Biphenyl Compounds; Cell Line; Disease Models, Animal; Mice; Neuroprotectiv | 2014 |
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, S | 2019 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Chitosan coated synergistically engineered nanoemulsion of Ropinirole and nigella oil in the management of Parkinson's disease: Formulation perspective and In vitro and In vivo assessment.
Topics: Animals; Benzoquinones; Chitosan; Disease Models, Animal; Drug Stability; Drug Synergism; Emulsions; | 2021 |
D-512, a novel dopamine D
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship | 2017 |
Intranasal and subcutaneous administration of dopamine D3 receptor agonists functionally restores nigrostriatal dopamine in MPTP-treated mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Intranasal; Animals; Corpus Striatum; | 2013 |
The anti-dyskinetic effect of dopamine receptor blockade is enhanced in parkinsonian rats following dopamine neuron transplantation.
Topics: Amphetamine; Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Benzazepines; Buspirone; Disease | 2014 |
Nano-ropinirole for the management of Parkinsonism: blood-brain pharmacokinetics and carrier localization.
Topics: Animals; Brain; Chemistry, Pharmaceutical; Disease Models, Animal; Dopamine; Dopamine Agonists; Dopa | 2015 |
Decreased HCN2 expression in STN contributes to abnormal high-voltage spindles in the cortex and globus pallidus of freely moving rats.
Topics: Animals; Antiparkinson Agents; Cardiovascular Agents; Cerebral Cortex; Disease Models, Animal; Down- | 2015 |
Duration of drug action of dopamine D2 agonists in mice with 6-hydroxydopamine-induced lesions.
Topics: Animals; Antiparkinson Agents; Apomorphine; Azepines; Benzothiazoles; Cabergoline; Corpus Striatum; | 2015 |
Oil based nanocarrier system for transdermal delivery of ropinirole: a mechanistic, pharmacokinetic and biochemical investigation.
Topics: Administration, Cutaneous; Administration, Oral; Animals; Antiparkinson Agents; Biological Availabil | 2012 |
Serotonergic and dopaminergic mechanisms in graft-induced dyskinesia in a rat model of Parkinson's disease.
Topics: 5,6-Dihydroxytryptamine; Adrenergic Agents; Amphetamine; Analysis of Variance; Animals; Antiparkinso | 2012 |
Evaluation of antidepressant activity of ropinirole coadministered with fluoxetine in acute and chronic behavioral models of depression in rats.
Topics: Acute Disease; Administration, Oral; Analysis of Variance; Animals; Antidepressive Agents; Behavior, | 2011 |
Ropinirole versus L-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson's disease: implications for dyskinesia.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dopamine A | 2004 |
S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity in comparison to ropinirole.
Topics: Acetylcholine; Animals; Callithrix; Cells, Cultured; Disease Models, Animal; Dopamine Agonists; Dopa | 2004 |
S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: III. Actions in models of potential antidepressive and anxiolytic activity in comparison with ropinirole.
Topics: Aggression; Animals; Anti-Anxiety Agents; Antidepressive Agents; Brain-Derived Neurotrophic Factor; | 2004 |
Selective blockade of D(3) dopamine receptors enhances the anti-parkinsonian properties of ropinirole and levodopa in the MPTP-lesioned primate.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzopyrans; Brain; Callithrix; Disease Model | 2004 |
Dopamine agonists suppress cholinomimetic-induced tremulous jaw movements in an animal model of Parkinsonism: tremorolytic effects of pergolide, ropinirole and CY 208-243.
Topics: Analysis of Variance; Animals; Cholinergic Agents; Disease Models, Animal; Dopamine Agonists; Dose-R | 2005 |
Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia.
Topics: Adenosine A2 Receptor Agonists; Adrenergic Agents; Amantadine; Animals; Antiparkinson Agents; Basal | 2005 |
Locomotion is increased in a11-lesioned mice with iron deprivation: a possible animal model for restless legs syndrome.
Topics: Animals; Brain Injuries; Diencephalon; Disease Models, Animal; Dopamine Agonists; Indoles; Iron; Iro | 2007 |
Overexpression of D2/D3 receptors increases efficacy of ropinirole in chronically 6-OHDA-lesioned Parkinsonian rats.
Topics: Adrenergic Agents; Animals; Animals, Genetically Modified; Antiparkinson Agents; Behavior, Animal; D | 2007 |
The frissonnant mutant mouse, a model of dopamino-sensitive, inherited motor syndrome.
Topics: Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Corpus Striatum; Disease Models, Anima | 2001 |
Behavioral and neurochemical effects of dopaminergic drugs in models of brain injury.
Topics: Animals; Behavior, Animal; Brain; Brain Injuries; Dihydroergocryptine; Disease Models, Animal; Dopam | 2002 |